<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452113</url>
  </required_header>
  <id_info>
    <org_study_id>1004003</org_study_id>
    <nct_id>NCT01452113</nct_id>
  </id_info>
  <brief_title>Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy</brief_title>
  <acronym>DPPNAC</acronym>
  <official_title>Effect of a DPP-IV Inhibitor Treatment on the Secretion of Glucagon in Patients Presenting With Type 1 Diabetes Mellitus With or Without Autonomic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Molecular Medicine of Rangueil (I2MR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculty of Medicine, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of a single administration of a DPP-IV&#xD;
      inhibitor (vildagliptin: Galvus ®) versus no treatment over two populations of diabetic&#xD;
      patients: without diabetic autonomic neuropathy (NA, i.e. the control group) and with&#xD;
      diabetic autonomic neuropathy (i.e. the neuropathy group). The investigators hypothesize that&#xD;
      the therapeutic efficacy of DPP-IV inhibitors is partly mediated by the autonomic nervous&#xD;
      system. This hypothesis will be validated if a lower glycemic response to DPP-IV inhibitor&#xD;
      treatment is observed for the neuropathy group compared to control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently published work has demonstrated in animals that the control of pancreatic hormone&#xD;
      secretion is due, at least in part, to the action of GLP-1 on the via the autonomic nervous&#xD;
      system. Therefore, rhe investigators hypothesized that altered autonomic nervous system could&#xD;
      explain, at least in part, the altered therapeutic efficacy of DPP-IV inhibitors observed in&#xD;
      some patients. Our aim is to validate this concept in humans.&#xD;
&#xD;
      The objective of this physiopathological, monocentric, comparative, open, parallel study is&#xD;
      to compare the effect of a single administration of a DPP-IV (vildagliptin: Galvus ®) over&#xD;
      two populations of type 1 diabetic patients: a control group of 12 patients without diabetic&#xD;
      autonomic neuropathy (NA) and a group of 12 patients with NA.&#xD;
&#xD;
      This proof of concept study will enrol type 1 diabetic patients to avoid confounding factors&#xD;
      related to endogen insulin secretion and frequent polymedication of type 2 diabetic patients.&#xD;
      The response will be evaluated for each patient by the relative difference between pre-and&#xD;
      post-glucagon concentrations following a test meal, measured in the absence and presence of&#xD;
      treatment with DPP4 inhibitor. Expected results: the DPP-4 inhibitor should lead to a&#xD;
      reduction of about 20 to 30% of the glucagon level in patients without NA and a smaller or no&#xD;
      decrease in patients with NA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma glucagon concentration</measure>
    <time_frame>120 min post stantardized meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>T-30, 0, 15, 30, 60, 90, 120, 180 min post standardized meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>T-30,0, 15, 30, 60, 90, 120, 180 min post standardized meal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>neuropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with autonomic neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients without autonomic neuropathy (ewing score &lt;= 0.5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>one 50 mg tablet per os</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>neuropathy</arm_group_label>
    <other_name>GALVUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type 1 diabetes mellitus&#xD;
&#xD;
          -  multiple daily insulin injections therapy or continuous insulin infusion (insulin&#xD;
             pomp) therapy&#xD;
&#xD;
          -  recent (&lt;1 year) written diagnosis of autonomic neuropathy available&#xD;
&#xD;
          -  ewing score &gt; 2 for patients to be included in the &quot;neuropathy&quot; group&#xD;
&#xD;
          -  ewing score &lt;= 0.5 for patients to be included in the '&quot;control&quot; group&#xD;
&#xD;
          -  HbA1C &lt;= 10% at the screening visit and stable (+/- 1%)between the autonomous&#xD;
             neuropathy diagnosis and the inclusion visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe chronic renal insufficiency defined by an estimated GFR&lt;30 ml/min calculated by&#xD;
             MDRD formula)&#xD;
&#xD;
          -  proliferative retinopathy needing panphotocoagulation&#xD;
&#xD;
          -  hepatic enzymes (ALAT, ASAT) greater than 3 times the upper limit&#xD;
&#xD;
          -  congestive heart failure of NYHA functional class III-IV&#xD;
&#xD;
          -  clinical signs of gastroparesis&#xD;
&#xD;
          -  ongoing gastric emptying therapy&#xD;
&#xD;
          -  history of bariatric surgery&#xD;
&#xD;
          -  galvus therapy contra indications: known allergy or hypersensitivity of princeps or&#xD;
             excipients, galactose intolerance, lapp lactase deficiency, glucose - galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  ongoing systemic corticoids therapy&#xD;
&#xD;
          -  metformin therapy during the day before each study visit&#xD;
&#xD;
          -  haemoglobin alteration&#xD;
&#xD;
          -  pregnancy or pregnancy willing&#xD;
&#xD;
          -  lactation&#xD;
&#xD;
          -  ongoing clinical study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remy Burcelin, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène Hanaire, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>DPP-IV protein</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>autonomic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

